source
- Supreme Court hints at ruling in case over generics' use of skinny-label drugsSupreme Court justices have offered preliminary signals about how they may decide a contentious lawsuit that could reshape the way generic drug makers market products with "skinny labels". The cas…
- FDA proposes removing semaglutide, tirzepatide, liraglutide from 503B compounding listThe FDA has proposed removing the active ingredients of several popular GLP‑1 drugs from the 503B compounding list. The agency says there is no clinical need for large compounding facilities to pr…